Pharmaceuticals, Biotechnology and Life Sciences
The European Commission (EC) has approved Novartis’ Cosentyx (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS.
The Swiss-based company Geistlich Pharma AG is recalling batch of Decalcit, vitamin D and calcium chewable tablets, from the market.
Bayer has submitted an application for marketing authorization in both the European Union and in the United States for LCS-16, a new low-dose levonorgestrel-releasing intrauterine system
Sanofi and AstraZeneca have announced a direct exchange of 210,000 compounds from their respective, proprietary compound libraries.
Mylan’s subsidiaries were sued Warner Chilcott and Qualicaps in connection with the filing of an ANDA with the FDA for Mesalamine Delayed-release Capsules.
Eli Lilly and Merck are moving on with an existing oncology clinical trial collaboration to evaluate the safety and efficacy of the combination of Lilly’s Almita (pemetrexed for injection) and Merck’s Keytruda (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).
Sanofi will participate to Solutions COP21, the United Nations conference on climate change, as an official partner, a public exhibition in Paris.
Biofrontera has concluded the clinical phase 3 of BCC study as the last patient in the ongoing phase has had its final clinical visit.
Amgen’s new injectable cholesterol drug Repatha has been turned down for use on Britain’s state health service, underscoring a worldwide debate about the value of such pricey medicines.
Advanced Oncotherapy has disposed of its subsidiary, Oncotherapy Resources Ltd (ORL), for a total cash consideration of £100,000 to Xstrahl.…